This clearance greatly expands the availability of NanoCept and represents the second 510(k) clearance since the original De Novo authorization. The most recent prior 510(k) clearance in October 2025 was for the ELEOS Proximal Tibia with NanoCept Antibacterial Technology.

NanoCept-coated implants are designed to support oncology and revision patients, populations that may face elevated risk for bacterial contamination due to patient and procedural factors.

By enabling NanoCept application to titanium, Onkos Surgical broadens access to antibacterial implant technology across a wider portion of the ELEOS system. The addition of an antibacterial surface to titanium implants commonly used in limb salvage procedures provides surgeons with another integrated option intended to address bacterial contamination on the implant surface prior to implantation.